VolitionRx and Werfen Collaborate on Antiphospholipid Syndrome Diagnosis

VolitionRx has signed a research and licensing agreement with Werfen to advance diagnostics for Antiphospholipid Syndrome (APS). The Nu.Q NETs assay will be explored for clinical utility in APS management, with Werfen planning to validate the test further and conduct a clinical utility study. This milestone aligns with Volition's strategy to out-license its proprietary Nu.Q NETs test to global diagnostics leaders.

VolitionRx Limited (NYSE AMERICAN: VNRX) has announced a significant milestone in its efforts to improve diagnostics for Antiphospholipid Syndrome (APS) by signing a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center Volition Signs First Human Out Licensing Deal - VolitionRx Ltd^[1]. The agreement will see Werfen gain access to Volition's proprietary Nu.Q® NETs assay to investigate its clinical utility in managing APS patients.

Under the terms of the agreement, Werfen will utilize Volition's Nu.Q® H3.1 NETs assay on its ACL AcuStar® platform to explore the clinical utility of the test in APS patients. Early results have shown promising detection of NETs levels in APS patients, indicating potential as a risk indicator for thrombosis . Marta Palicio, Werfen's Immunoassay Technology Center Innovation R&D Director, expressed enthusiasm about the collaboration, stating that further validation and a clinical utility study are planned to determine the test's role in APS management Volition Signs First Human Out Licensing Deal - VolitionRx Ltd^[1].

APS is a complex autoimmune disorder affecting approximately four million people worldwide, characterized by an increased risk of blood clots and associated complications such as stroke, heart attack, and deep vein thrombosis . The current diagnostic process involves a panel of blood tests, requiring two positive results at least 12 weeks apart, and is often a lifelong condition necessitating regular monitoring .

Volition's Chief Commercial Officer, Gael Forterre, highlighted the strategic importance of the agreement, stating, "We are proud to have entered into this agreement with Werfen as we implement our strategy to out-license our proprietary Nu.Q® NETs test to large worldwide companies. Werfen's expertise in specialized diagnostics aligns well with our goals" Volition Signs First Human Out Licensing Deal - VolitionRx Ltd^[1]. This collaboration is part of Volition's broader strategy to leverage global diagnostics leaders' knowledge and installed base of proprietary analyzers to advance its diagnostic technologies.

This agreement marks a significant step forward in Volition's mission to save lives and improve outcomes for people with life-altering diseases through earlier detection and monitoring. The company aims to provide a low-cost, effective diagnostic tool for APS patients, potentially revolutionizing the way the condition is managed.

References:
Volition Signs First Human Out Licensing Deal - VolitionRx Ltd^[1] https://ir.volition.com/news-events/press-releases/detail/852/volition-signs-first-human-out-licensing-deal
Ayesha Butt, Anish Sharda, Alfred Ian Lee, Jason S Knight, Analytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome, Transfusion Medicine Reviews, 2025, https://doi.org/10.1016/j.tmrv.2025.150909